Indeed, in mouse and rat models, it has been demonstrated that treatment of pulmonary hypertension with an anti‐NOTCH3 antibody (Ab 28 042), which specifically binds to NOTCH3 and inhibits JAGGED1‐induced NOTCH3 cleavage, has no evident toxic side effects [20]. The gene discussed is JAG1; the disease is pulmonary arterial hypertension.